美国Mylan Labs
MYLAN公司始建于1961年，总部设在美国宾夕法尼亚州匹兹堡市，公司股票在美国纽约证券交易所上市。MYLAN的产品范围涵盖普药、专利药和医药原料，品种多达570多种，是全球领先的非专利药和特效药生产商之一。MYLAN公司在2007年5月收购了印度MATRIX集团，并于同年10月完成了令世界制药行业瞩目的并购——以50亿欧元收购了全球第二大跨国公司——默克公司的通用名药物部门，从而跻身为全球第二大原料药供应商和第三大跨国性的非专利药品生产商。MYLAN的商业领域遍布全球90多个国家，目前员工遍布全球各大洲，人数超过12000人。2007年MYLAN的销售额近48亿美元。

Mylan is one of the world’s leading generics and specialty pharmaceutical companies, providing products to customers in more than 140 countries and territories. The company maintains one of the industry’s broadest and highest quality product portfolios, which is regularly bolstered by an innovative and robust product pipeline. With approximately 15,500 employees, Mylan has attained leading positions in key international markets through its wide array of dosage forms and delivery systems, significant manufacturing capacity, global commercial scale and a committed focus on quality and customer service. The company ranks among the top five generics companies in several markets around the world and is the largest U.S.-based generics manufacturer in the world.

Through its subsidiary Matrix Laboratories, Mylan has direct access to one of the world’s largest active pharmaceutical ingredient (API) manufacturers. This relationship makes Mylan one of only two global generics companies with a comprehensive, vertically integrated supply chain. Matrix also is one of the world’s largest producers of API used to make generic antiretroviral (ARV) therapies for the treatment of HIV/AIDS.

Additionally, Mylan operates a fully integrated specialty pharmaceutical business, Dey Pharma, which produces innovative medicinal therapies, including EpiPen® Auto-Injector.